A serious adverse event (SAE) occurs in a clinical trial, potentially linked to the investigational product. Outline your immediate steps, the stakeholders you would inform, and the decision-making process you would follow to ensure patient safety, regulatory reporting, and data integrity, considering the potential impact on the trial's continuation.
final round · 5-7 minutes
How to structure your answer
MECE Framework: 1. Immediate Action: Assess patient, stabilize, notify PI/medical monitor. 2. Data Collection: Document event details (onset, severity, causality, treatment, outcome) using CRF/source. 3. Reporting: Expedited reporting to IRB/EC, Sponsor, FDA/competent authorities within timelines (e.g., 24h for fatal/life-threatening). 4. Stakeholder Communication: Inform study team, sponsor, regulatory affairs. 5. Decision-Making (CIRCLES Framework): Evaluate causality, risk-benefit, protocol adherence. Determine if trial modification (e.g., dose adjustment, temporary halt, unblinding) or termination is warranted, prioritizing patient safety and data integrity. 6. Follow-up: Monitor patient, ensure ongoing reporting.
Sample answer
Upon an SAE, I'd immediately activate the MECE Framework. First, I'd ensure immediate patient safety and stabilization, notifying the Principal Investigator (PI) and medical monitor. Simultaneously, I'd meticulously document all event details, including onset, severity, causality assessment by the PI, treatment, and outcome, utilizing the CRF and source documents. My next step involves expedited reporting to the Institutional Review Board (IRB)/Ethics Committee (EC), Sponsor, and relevant regulatory authorities (e.g., FDA) within their mandated timelines (e.g., 24 hours for fatal/life-threatening events). Stakeholders informed would include the study team, sponsor's safety department, and regulatory affairs. The decision-making process, guided by the CIRCLES Framework, would involve the PI and medical monitor evaluating causality, the overall risk-benefit profile, and protocol adherence. This assessment determines if trial modifications (e.g., dose adjustment, temporary halt, unblinding) or, in severe cases, trial termination is necessary, always prioritizing patient safety and data integrity. Ongoing patient monitoring and follow-up reporting are critical.
Key points to mention
- • Adherence to protocol-defined SAE reporting timelines (e.g., 24-hour initial notification).
- • Thorough documentation and source data verification.
- • Understanding of causality assessment and its implications.
- • Knowledge of regulatory reporting requirements (FDA, ICH-GCP, local regulations).
- • Prioritization of patient safety above all else.
- • Role of the IRB/EC and DSMB in safety oversight.
Common mistakes to avoid
- ✗ Delay in reporting the SAE to the PI or sponsor.
- ✗ Incomplete or inaccurate documentation of the event.
- ✗ Failure to follow up on the SAE's resolution or long-term outcome.
- ✗ Not understanding the difference between an AE and an SAE.
- ✗ Assuming causality without PI's assessment.
- ✗ Bypassing the PI for direct sponsor communication regarding medical decisions.